Accumulation of fat in the liver is the first and reversible event that occurs within the physio-pathological progression from a healthy liver to NASH. This abnormal and significant lipid accumulation in the organ, referred to hepatic steatosis, Simple Steatosis (SS) or (Non-Alcoholic) Fatty Liver (NAFL), is the consequence of a dramatic increase of free fatty acid fluxes into the organ.

GlobalData reported about 70M prevalent cases of NASH in the 7 major markets (MM) in 2019. The global NASH market accounted for 174.8M$ in 2021 and it is expected to reach a value of 27$ by 2031 showing a growth trend in the following years with a CAGR of 58%. Major players in these areas have been identified.